CN1418685A - Medicine composition for treating and its prepn. method - Google Patents
Medicine composition for treating and its prepn. method Download PDFInfo
- Publication number
- CN1418685A CN1418685A CN 02153460 CN02153460A CN1418685A CN 1418685 A CN1418685 A CN 1418685A CN 02153460 CN02153460 CN 02153460 CN 02153460 A CN02153460 A CN 02153460A CN 1418685 A CN1418685 A CN 1418685A
- Authority
- CN
- China
- Prior art keywords
- parts
- treatment
- pharmaceutical composition
- condyloma acuminatum
- podophyllotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title claims description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 22
- 206010059313 Anogenital warts Diseases 0.000 claims abstract description 13
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims abstract description 11
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 11
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims abstract description 11
- 229960001237 podophyllotoxin Drugs 0.000 claims abstract description 11
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 11
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- -1 filtered Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000000890 drug combination Substances 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004500 asepsis Methods 0.000 description 5
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000006916 nutrient agar Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001572 anti-trichomonad Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 208000003796 chancre Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicine composite for curing pointed condyloma and its preparation method. It is made of the Chinese medicinal material flavescent sophora root, salicylic acid, podophyllotoxin and borneol.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of condyloma acuminatum and preparation method thereof.
Condyloma acuminatum is one of current common sexually transmitted disease (STD), and the traditional Chinese medical science is referred to as " condyloma acuminatum ", " urine wart ".The traditional Chinese medical science thinks that condyloma acuminatum is that it is unclean to join owing to deficiency of both the liver and kidney, the damp and hot excessive poison of diseases caused by exogenous pathogenic factor, and due to noxious dampness was made a bet, its pathogenesis main points were noxious dampness stasis of blood knot.Treatment is based on heat-clearing and toxic substances removing, damp eliminating eliminating stagnation, corrosion warty vegetation.Genital herpes is a kind of sexually transmitted disease (STD) that is caused by herpes simplex virus HSV, belongs to the category of the traditional Chinese medical science " herpes simplex ", " chancre ".The traditional Chinese medical science thinks that primary disease is that sexual intercourse is unclean, and it is evil to infect foul damp and hot poison, and damp invasion of lower energizer pents up skin and forms.Treatment is based on clearing away heat-damp and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body.
The object of the invention is to provide a kind of evident in efficacy have heat-clearing and toxic substances removing, external used medicine of effects such as blood stasis-eliminating and stagnation-dissipating and preparation method thereof.
Technical solution of the present invention is achieved in that
Bulk drugs as described below:
50～150 parts of 50～150 parts of salicylic acid of Radix Sophorae Flavescentis
1～5 part of 2.5～7.5 parts of Borneolum Syntheticum of podophyllotoxin
Radix Sophorae Flavescentis is with 95% alcohol reflux 2 times, and 2 hours for the first time, 1.5 hours for the second time, merge extractive liquid, filtered, and concentrates.Other gets Borneolum Syntheticum, salicylic acid, podophyllotoxin and uses an amount of dissolve with ethanol respectively, is added to extract in the concentrated solution, adds 250～750ml PEG400 again, and mixing is adjusted to full dose, packing, promptly.
Through laboratory observation, the result shows pharmaceutical composition tool antibacterial action of the present invention, and is all inhibited to each bacterium; Just can play antibacterial action than low dosage; Each strain had in various degree minimum inhibitory concentration; Staphylococcus aureus there is certain bactericidal action.Have infusorian effect extremely, its anti-trichomonal effect and its dosage are proportionate.High and low dose all has the effect of obvious inhibition rat paw edema.Mice auricle swelling due to the high low dosage xylol all has the obvious suppression effect.HSV-2 is had deactivation, and the deactivation index reached is more than 166.0; Can reduce the fatality rate of the mice of experimental infection HSV-2.
Pharmaceutical composition of the present invention has thermal detoxification, and effects such as blood stasis-eliminating and stagnation-dissipating can be used for condyloma acuminatum, treatment of conditions such as genital herpes.Experimental example 1: antibacterial tests:
1) sterility test: get pharmaceutical composition of the present invention with normal saline dilution and add in antibacterial and the mycete Nutrient agar and make the medicine final concentration become 1: 10,1: 100,1: 1000, pour plate, each concentration is done three groups.Put 37 ℃ of incubators and cultivated 7 days, observing has asepsis growth and meter clump count.
The result: each dilution factor asepsis growth does not detect antibacterial.
2) bacteriostatic test: get each strain separate application antibacterial, mycete or gc agar flat board, with the punching of aperture 5mm card punch, get pharmaceutical composition of the present invention and fill it up with in each hole, every bacterium branch is done three groups.Put 37 ℃ and cultivate survey after 24 hours but loop diameter.
The result: pharmaceutical composition of the present invention is all inhibited to each bacterium.
3) minimum inhibitory concentration (MIC) test: the Nutrient agar dilution method with normal saline dilution pharmaceutical composition of the present invention, and adds Nutrient agar and makes the medicine final concentration become 1/10,1/20,1/30,1/40,1/50, pour plate behind the mixing.Dilute each bacterium with normal saline and become 300,000,000/ml, respectively get an inoculation ring species on each concentration medicine flat board, each bacterium is cooked three groups.Cultivate 24 hours observed results for 37 ℃.
The result: with the high dilution of three groups of medicines of testing the growth of equal integral asepsis is its minimum inhibitory concentration (MIC).Pharmaceutical composition of the present invention has in various degree minimum inhibitory concentration to each strain.
4, minimum bactericidal concentration (MBC) test, the agar kind that extracts the inoculated bacteria place of asepsis growth in the MIC test are cultivated 24 hours observed results for 37 ℃ in nutrient agar panel.With the high dilution of the medicine of integral asepsis growth is its minimum bactericidal concentration (MBC).
The result: pharmaceutical composition of the present invention has certain bactericidal action to staphylococcus aureus.Experimental example 2: anti-trichomonal test
Become 90%, 50%, 25%, 10%, 5% concentration with culture medium dilution pharmaceutical composition of the present invention.Getting infusorian adds in each concentration pharmaceutical composition culture medium of the present invention, in the different time observed result.In the shortest time, kill the high dilution of medicine of infusorian with medicine fully and judge that it kills the infusorian effect.
The result: pharmaceutical composition of the present invention has infusorian effect extremely, and its anti-trichomonal effect and its dosage are proportionate.
Embodiment 1:
Radix Sophorae Flavescentis 100g salicylic acid 100g
Podophyllotoxin 5g Borneolum Syntheticum 2g
Radix Sophorae Flavescentis is with 95% alcohol reflux 2 times, and 2 hours for the first time, 1.5 hours for the second time, merge extractive liquid, filtered, and concentrates.Other gets Borneolum Syntheticum, salicylic acid, podophyllotoxin and uses an amount of dissolve with ethanol respectively, is added to extract in the concentrated solution, adds the 500ml PEG400 again, and mixing is adjusted to 1000ml, packing, promptly.
Embodiment 2:
Radix Sophorae Flavescentis 120g salicylic acid 80g
Podophyllotoxin 5g Borneolum Syntheticum 3g
Radix Sophorae Flavescentis is with 95% alcohol reflux 2 times, and 2 hours for the first time, 1.5 hours for the second time, merge extractive liquid, filtered, and concentrates.Other gets Borneolum Syntheticum, salicylic acid, podophyllotoxin and uses an amount of dissolve with ethanol respectively, is added to extract in the concentrated solution, adds the 500ml PEG400 again, and mixing is adjusted to 1000ml, packing, promptly.
Claims (6)
1, a kind of pharmaceutical composition for the treatment of condyloma acuminatum is characterized in that this pharmaceutical composition made by following bulk drugs:
50～150 parts of 50～150 parts of salicylic acid of Radix Sophorae Flavescentis
1～5 part of 2.5～7.5 parts of Borneolum Syntheticum of podophyllotoxin
2, a kind of pharmaceutical composition for the treatment of condyloma acuminatum as claimed in claim 1 is characterized in that this pharmaceutical composition made by bulk drugs as described below:
100 parts of 100 parts of salicylic acid of Radix Sophorae Flavescentis
2 parts of 5 parts of Borneolum Syntheticums of podophyllotoxin
3, as claim 1,2 described a kind of preparation of drug combination methods for the treatment of condyloma acuminatum, it is characterized in that this method is: Radix Sophorae Flavescentis alcohol reflux 2 times, 2 hours for the first time, 1.5 hours for the second time, merge extractive liquid, filtered, and concentrates.Other gets Borneolum Syntheticum, salicylic acid, podophyllotoxin and uses an amount of dissolve with ethanol respectively, is added to extract in the concentrated solution, adds appropriate amount of auxiliary materials again, and mixing is adjusted to full dose, packing, promptly.
4, a kind of preparation of drug combination method for the treatment of condyloma acuminatum as claimed in claim 3 is characterized in that this method is: Radix Sophorae Flavescentis alcohol reflux 2 times, 2 hours for the first time, 1.5 hours for the second time, merge extractive liquid, filtered, and concentrates.Other gets Borneolum Syntheticum, salicylic acid, podophyllotoxin and uses an amount of dissolve with ethanol respectively, is added to extract in the concentrated solution, adds appropriate amount of auxiliary materials again, and mixing is adjusted to full dose, packing, promptly.
5, as claim 3,4 described a kind of preparation of drug combination methods for the treatment of condyloma acuminatum, the consumption that it is characterized in that the adjuvant PEG400 is 250～750ml.
6, a kind of preparation of drug combination method for the treatment of condyloma acuminatum as claimed in claim 5, the consumption that it is characterized in that the adjuvant PEG400 is 500ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021534608A CN1187073C (en) | 2002-11-29 | 2002-11-29 | Medicine composition for treating and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021534608A CN1187073C (en) | 2002-11-29 | 2002-11-29 | Medicine composition for treating and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1418685A true CN1418685A (en) | 2003-05-21 |
| CN1187073C CN1187073C (en) | 2005-02-02 |
Family
ID=4752260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021534608A Expired - Lifetime CN1187073C (en) | 2002-11-29 | 2002-11-29 | Medicine composition for treating and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1187073C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833674B (en) * | 2006-01-11 | 2010-09-08 | 北京因科瑞斯生物制品研究所 | Wart gel and preparation method |
| CN102048751B (en) * | 2009-10-28 | 2013-05-15 | 邢淑艳 | Medicine for treating venereal disease |
| CN103784946A (en) * | 2014-02-16 | 2014-05-14 | 王海英 | Medicinal composition for treating verruca acuminata |
| CN104971266A (en) * | 2014-10-11 | 2015-10-14 | 淮安御传堂生物科技有限公司 | Traditional Chinese medicine aqueous agent for treating condyloma acuminata and preparation method thereof |
| CN108310072A (en) * | 2018-02-07 | 2018-07-24 | 嘉善县圣康生物科技有限公司 | One kind removing wart external ointment |
-
2002
- 2002-11-29 CN CNB021534608A patent/CN1187073C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833674B (en) * | 2006-01-11 | 2010-09-08 | 北京因科瑞斯生物制品研究所 | Wart gel and preparation method |
| CN102048751B (en) * | 2009-10-28 | 2013-05-15 | 邢淑艳 | Medicine for treating venereal disease |
| CN103784946A (en) * | 2014-02-16 | 2014-05-14 | 王海英 | Medicinal composition for treating verruca acuminata |
| CN103784946B (en) * | 2014-02-16 | 2016-06-08 | 王海英 | A kind of pharmaceutical composition treating condyloma acuminatum |
| CN104971266A (en) * | 2014-10-11 | 2015-10-14 | 淮安御传堂生物科技有限公司 | Traditional Chinese medicine aqueous agent for treating condyloma acuminata and preparation method thereof |
| CN104971266B (en) * | 2014-10-11 | 2018-05-29 | 淮安御传堂生物科技有限公司 | A kind of Chinese medicinal aqua for treating condyloma acuminatum and preparation method thereof |
| CN108310072A (en) * | 2018-02-07 | 2018-07-24 | 嘉善县圣康生物科技有限公司 | One kind removing wart external ointment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1187073C (en) | 2005-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104082353A (en) | Pure traditional Chinese medicine disinfectant and preparation method thereof | |
| CN1173820A (en) | Pharmaceutical composition for the treatment of herpes | |
| CN109452320A (en) | The purposes of Fructus Caryophylli volatile oil | |
| Soković et al. | Antifungal activity of the essential oils and components in vitro and in vivo on experimentally induced dermatomycoses at rats | |
| CN102948434A (en) | Aquaculture sterilization parasiticide | |
| CN109288889A (en) | A kind of antibacterial gynecological composition, gel and preparation method thereof | |
| CN110314178A (en) | Pure natural compound essential oil and its preparation and use with broad spectrum antibacterial activity | |
| US20100233285A1 (en) | Honey based compositions of a consistency that can be delivered to the respiratory system | |
| CN1187073C (en) | Medicine composition for treating and its prepn. method | |
| CN102283257A (en) | Application of elephantopus tomentosus in preventing and treating tobacco bacterial wilt | |
| CN104083433B (en) | Treat animal psoroptic mange external application Chinese veterinary medicinal composition, using and preparation method thereof | |
| CN109287677A (en) | The purposes of flos caryophylli volatile oil | |
| CN105012581A (en) | Fresh aloe antibacterial composite, application and preparing method of fresh aloe antibacterial composite | |
| CN102600195A (en) | Composite transdermal linimentum for pets as well as preparation method and application of composite transdermal linimentum | |
| CN103550303B (en) | Pharmaceutical composition for preventing and treating canine otitis externa | |
| CN1426811A (en) | Action of litsea citrate oil in killing parasite on human body and animal | |
| CN104000767B (en) | A kind of Feminine care solution and preparation method thereof | |
| WO2006029605A1 (en) | Method and active ingredient for combating plasmodia | |
| CN112516237A (en) | Sterilization and deodorization spray for pets and preparation method thereof | |
| CN105125536B (en) | Treat bacterium, fungi, virus or dermopathic composition caused by parasite | |
| CN1400004A (en) | Chinese medicine preparation for curing chronic conjunctivitis | |
| CN101411749B (en) | Chinese medicinal composition for treating nasal sinusitis and allergic rhinitis | |
| Chakma et al. | Traditional uses of Ethno-medicinal Plants in Chittagong Hill Tracts (CHTs), Bangladesh: A Review | |
| CN1416859A (en) | Externally applied Chinese medicine with functions of diminishing inflammation, promoting granulation, stopping itch and stopping pain and its prepn process | |
| Olorode et al. | Efficacy of Nigerian Local Honey on Pseudomonas Aeruginosa from Infected Wound among Genders in Federal Medical Center, Bayelsa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: QIYUANYIDE MEDICINES INST., BEIJING Free format text: FORMER OWNER: ZHANG HUIFANG Effective date: 20030812 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20030812 Address after: 100027, Beijing, Chaoyang District, East Third Ring Road, Xin 2, di Yang building, room 10, 1007A Applicant after: Beijing Qi Yuan Yi De Pharmaceuticals Research Center Address before: 100027, Beijing, Chaoyang District, East Third Ring Road, Xin 2, di Yang building, room 10, 1007A Applicant before: Zhang Huifang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Guizhou Baixiang Pharmaceutical Co.,Ltd. Assignor: Beijing Qi Yuan Yi De Pharmaceuticals Research Center Contract fulfillment period: 2006.4.15 to 2013.4.15 Contract record no.: 2008990000875 Denomination of invention: Medicine composition for treating and its prepn. method Granted publication date: 20050202 License type: Exclusive license Record date: 20081022 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2006.4.15 TO 2013.4.15; CHANGE OF CONTRACT Name of requester: GUIZHOU BAIXIANG PHARMACEUTICAL CO. Effective date: 20081022 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Guizhou Baixiang Pharmaceutical Co.,Ltd. Assignor: Beijing Qi Yuan Yi De Pharmaceuticals Research Center Contract record no.: 2008990000875 Date of cancellation: 20111214 |
|
| ASS | Succession or assignment of patent right |
Owner name: HANFANG PHARMACEUTICAL CO., LTD., GUIZHOU Free format text: FORMER OWNER: QIYUANYIDE MEDICINES INST., BEIJING Effective date: 20120223 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100027 CHAOYANG, BEIJING TO: 550002 GUIYANG, GUIZHOU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120223 Address after: Nanming District of Guiyang city in 550002 of the 45 South Road, building 19 floor Huakun development Patentee after: GUIZHOU HANFANG PHARMACEUTICAL Co.,Ltd. Address before: 100027, Beijing, Chaoyang District, East Third Ring Road, Xin 2, di Yang building, room 10, 1007A Patentee before: Beijing Qi Yuan Yi De Pharmaceuticals Research Center |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190329 Address after: 550029 Jinyang Science and Technology Industrial Park, Guiyang High-tech Industrial Development Zone, Guizhou Province (No. 11 Duyun Road) Patentee after: HANFANG PHARMA CO.,LTD. Address before: 19 Floor, Huakun Development Building, 45 South China Road, Nanming District, Guiyang City Patentee before: GUIZHOU HANFANG PHARMACEUTICAL Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition for treating and its prepn. method Effective date of registration: 20200519 Granted publication date: 20050202 Pledgee: Guizhou mingdekang Technology Center (L.P.) Pledgor: HANFANG PHARMA Co.,Ltd. Registration number: Y2020520000006 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220428 Granted publication date: 20050202 Pledgee: Guizhou mingdekang Technology Center (L.P.) Pledgor: HANFANG PHARMA CO.,LTD. Registration number: Y2020520000006 |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050202 |
|
| CX01 | Expiry of patent term |